Unicycive Therapeutics, Inc. (UNCY) shareholders
Close on Nov 18, 2026Market cap $99.44MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (9.99%) | 60,961,729 | 9.99% | 13G (passive) amendment | Mar 31, 2025 |
| Great Point Partners, LLC Joint filing with Dr. Jeffrey R. Jay, M.D. (9.99%), Ms. Lillian Nordahl (9.99%) | 11,473,166 | 9.99% | 13G (passive) amendment | Dec 31, 2024 |
| Wilmot B. Harkey Joint filing with Nantahala Capital Management, LLC (9.99%), Daniel Mack (9.99%) | 10,879,142 | 9.99% | 13G (passive) amendment | Dec 19, 2024 |
| Vivo Opportunity, LLC Joint filing with Vivo Opportunity Fund Holdings, L.P. (9.99%) | 4,856,259 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Daniel Mack Joint filing with Nantahala Capital Management, LLC (9.99%), Wilmot B. Harkey (9.99%) | 2,807,830 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Peter Kolchinsky Joint filing with RA Capital Management, L.P. (9.90%), Rajeev Shah (9.90%) and 1 more | 2,801,082 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Rajeev Shah Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 1,960,230 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| Nantahala Capital Management, LLC Joint filing with Wilmot B. Harkey (9.99%), Daniel Mack (9.99%) | 1,855,991 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Lampert Mark N Joint filing with Bvf Partners L P/Il (9.99%), Bvf Inc/Il (9.99%) and 3 more | 1,417,117 | 9.99% | 13G (passive) amendment | Jun 30, 2025 |
| BlackRock, Inc. | 1,413,381 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Integrated Core Strategies (US) LLC Joint filing with Millennium Management LLC (5.50%), Millennium Group Management LLC (5.50%) and 1 more | 1,172,667 | 5.50% | 13G (passive) | Jan 16, 2026 |
| Ms. Lillian Nordahl Joint filing with Great Point Partners, LLC (6.24%), Dr. Jeffrey R. Jay, M.D. (6.24%) | 796,558 | 6.24% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of UNCY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 2,802,894 | 10.06% | $13.15M | +1,863,692 | 0.22% |
| BlackRock, Inc. | 1,413,381 | 5.07% | $6.63M | +1,377,478 | 0.00% |
| Vanguard Capital Management LLC | 1,071,481 | 3.85% | $5.03M | +260,051 | 0.00% |
| Octagon Capital Advisors LP | 1,000,000 | 3.59% | $4.69M | – | 0.42% |
| Geode Capital Management, LLC | 564,019 | 2.02% | $2.65M | +360,275 | 0.00% |
| Vivo Capital, LLC | 550,000 | 1.97% | $2.58M | −1,239,916 | 0.24% |
| Marshall Wace, Llp | 547,862 | 1.97% | $2.57M | +392,924 | 0.00% |
| Logos Global Management LP | 473,563 | 1.70% | $2.22M | – | 0.10% |
| State Street Corp | 450,162 | 1.62% | $2.11M | +370,135 | 0.00% |
| Diametric Capital, LP | 374,132 | 1.34% | $1.75M | +293,770 | 0.19% |
| J. Goldman & Co LP | 327,345 | 1.18% | $1.54M | New | 0.04% |
| Diadema Partners LP | 303,676 | 1.09% | $1.42M | +197,593 | 0.18% |
| Millennium Management LLC | 271,456 | 0.97% | $1.27M | −1,127,892 | 0.00% |
| Dauntless Investment Group, LLC | 214,000 | 0.77% | $1.00M | +66,913 | 0.79% |
| Citigroup Inc | 182,654 | 0.66% | $856.65K | +182,653 | 0.00% |
| Northern Trust Corp | 181,930 | 0.65% | $853.25K | +145,993 | 0.00% |
| Vanguard Portfolio Management LLC | 169,196 | 0.61% | $793.53K | New | 0.00% |
| Susquehanna International Group, Llp | 160,039 | 0.57% | $750.58K | −39,180 | 0.00% |
| Jump Financial, LLC | 153,000 | 0.55% | $717.57K | New | 0.01% |
| Vanguard Fiduciary Trust Co | 148,965 | 0.53% | $698.65K | +47,891 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 80 | 13M | 46.9% | 36 / 23 | 11 / 7 | 7M | 4M |
| Q1 2026 | 51 | 10M | 35.6% | 20 / 10 | 11 / 3 | 3M | 0M |
| Q4 2025 | 35 | 8M | 29.6% | 8 / 8 | 6 / 2 | 2M | 0M |
| Q3 2025 | 30 | 6M | 22.6% | 13 / 9 | 1 / 3 | 1M | 0M |
| Q2 2025 | 20 | 5M | 18.5% | 20 / 0 | 0 / 0 | 5M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
62 funds held UNCY in Q2 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of UNCY | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 805,716 | 2.89% | $3.78M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 616,216 | 2.21% | $2.89M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 268,848 | 0.97% | $1.35M | 0.00% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 240,017 | 0.86% | $1.13M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 201,744 | 0.72% | $946.18K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 84,554 | 0.30% | $624.01K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 81,976 | 0.29% | $384.47K | 0.03% | Jun 30, 2026 |
| Dimensional U.S. Small Cap ETF | 67,827 | 0.24% | $339.81K | 0.00% | Jul 31, 2026 |
| Schwab Small-Cap Index Fund | 54,842 | 0.20% | $274.76K | 0.00% | Jul 31, 2026 |
| Master Small Cap Index Series | 45,675 | 0.16% | $214.22K | 0.00% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 33,059 | 0.12% | $165.63K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 26,975 | 0.10% | $199.08K | 0.00% | May 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 26,528 | 0.10% | $124.42K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 24,577 | 0.09% | $181.38K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Value ETF | 23,641 | 0.08% | $110.88K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shalabh K. Gupta | CEO, Director | 5,973,471 | 21.44% | Jun 15, 2026 |
| Douglas Jermasek | EVP, Corporate Strategy | 175,012 | 0.63% | Jun 15, 2026 |
| John Townsend | CFO | – | – | Jun 15, 2026 |
| Pramod Gupta | EVP, Pharmaceuticals and BD | 41,845 | 0.15% | Jun 15, 2026 |
| Meredith Manning | Director | – | – | Oct 29, 2026 |
| Sandeep Laumas | Director | 105,815 | 0.38% | Jul 28, 2026 |
| Sara Kenkare-Mitra | Director | – | – | Jul 28, 2026 |
| Gaurav Aggarwal | Director | 1,789,915 | 6.43% | Aug 26, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gaurav Aggarwal Director | Aug 25, 2025 | Conversion | +652,900 | – | – | 1,789,915 |
| Gaurav Aggarwal Director | Feb 18, 2025 | Conversion | +1,400,000 | – | – | 11,370,152 |
| Gaurav Aggarwal Director | Oct 9, 2024 | Conversion | +5,500,000 | – | – | 9,970,152 |
| Gaurav Aggarwal Director | Jul 11, 2023 | Conversion | +3,470,152 | – | – | 3,470,152 |
| Pramod Gupta EVP, Pharmaceuticals and BD | Jul 11, 2023 | Option exercise | +41,845 | – | – | 41,845 |
| Douglas Jermasek EVP of Corporate Strategy | Jul 11, 2023 | Option exercise | +104,612 | – | – | 175,012 |
| Shalabh K. Gupta CEO, Director | Jul 11, 2023 | Option exercise | +104,612 | – | – | 2,527,449 |
| Brigitte Schiller Director | Jul 15, 2022 | Option exercise | +26,738 | – | – | 26,738 |
| Brigitte Schiller Director | May 16, 2022 | Buy | +15,000 | $0.83 | $12.45K | 15,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Unicycive Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 36,281 shares on Oct 5, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. Director | Jul 1, 2026 | 1,789,916 | $9.45M | Jun 30, 2026 | PIPE |
See a number that looks wrong?